We were very surprised to learn that PRKCD (Fig. 7H) and RPS6KA1 (Fig. 7I) have been used as targets in drug studies.[31,32] For example, tamoxifen, which targets PRKCD, has been used to treat advanced breast and ovarian cancers.[33] Furthermore, we found through the DrugBank database (https://go.drugbank.com/) that Fostamatinib has been used as an inhibitor of RPS6KA1 for the treatment of chronic immune thrombocytopenia. The gene discussed is RPS6KA1; the disease is ovarian carcinoma.